Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CBB1 plus rabies vaccine in healthy adults
CTR20242565Phase 2Completed
- Sponsor
- Changchun Baimu Biotechnology
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CBB1 in rabies, sponsored by Changchun Baimu Biotechnology. Started Jul 2024; status: completed.
02
Drugs
CBB1
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20242565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242565.